GlassScriptPhysician profile
Cheree Cuellar
NPI 1538616867
$4,363.65
in general payments reported to CMS, 2019-2025
26 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $1,387 · 2023: $1,853 · 2024: $569 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $538.56 | 2021-2024 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $437.48 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $419.03 | 2022-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $414.43 | 2022-2025 | Jynarque |
| Horizon Therapeutics Plc | $273.06 | 2022-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $212.54 | 2022-2024 | |
| Glaxosmithkline, LLC. | $207.22 | 2022-2024 | Benlysta, Arexvy, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $201.26 | 2022-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $187.30 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $172.44 | 2022-2023 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $121.34 | 2021 | |
| Amgen INC. | $119.27 | 2023-2025 | Parsabiv, Sensipar, Tavneos |
| Genzyme Corporation | $116.72 | 2023 | |
| Daiichi Sankyo INC. | $116.59 | 2023 | Injectafer |
| Calliditas Therapeutics US INC. | $115.42 | 2023 | Tarpeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $111.17 | 2022 | |
| Ani Pharmaceuticals, INC. | $108.10 | 2024 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $104.69 | 2023 | Gemtesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.65 | 2023 | |
| Medtronic, INC. | $71.43 | 2022 | |
| Shield Therapeutics INC | $61.41 | 2024 | |
| Ardelyx, INC. | $53.95 | 2024-2025 | Ibsrela |
| Outset Medical INC | $28.08 | 2025 | |
| Nxstage Medical, INC. | $27.50 | 2024 | |
| Kyowa Kirin, INC. | $25.05 | 2025 | |
| Merck Sharp & Dohme LLC | $20.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheree Cuellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.